EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Early metformin treatment: An effective approach for targeting fragile X syndrome pathophysiology

Jung-Hyun Choi iD, Laura Marsal-García iD, Eve Peraldi iD, Caleb Walters, Ziying Huang, Ilse Gantois iD, Nahum Sonenberg iD

Proceedings of the National Academy of Sciences · 2024

DOI: 10.1073/pnas.2407546121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Jung-Hyun Choi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Goodman Cancer Institute, McGill University, Montreal, QC H3A 1A3, Canada. Hauptthemen laut MEDLINE: Metformin, Fragile X Syndrome, Fragile X Messenger Ribonucleoprotein 1. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Government | Canadian Institutes of Health Research (CIHR), National Research Foundation of Korea (NRF), FRAXA Research Foundation (FRF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fragile X syndrome (FXS) is the most common genetic cause of autism spectrum disorder engendered by transcriptional silencing of the fragile X messenger ribonucleoprotein 1 ( FMR1 ) gene. Given the early onset of behavioral and molecular changes, it is imperative to know the optimal timing for therapeutic intervention. Case reports documented benefits of metformin treatment in FXS children between 2 and 14 y old. In this study, we administered metformin from birth to Fmr1 −/y mice which corrected up-regulated mitogen-2 activated protein kinase/extracellular signal-regulated kinase and mammalian/mechanistic target of rapamycin complex 1 signaling pathways and specific synaptic mRNA-binding targets of FMRP. Metformin rescued increased number of calls in ultrasonic vocalization and repetitive behavior in Fmr1 −/y mice. Our findings demonstrate that in mice, early-in-life metformin intervention is effective in treating FXS pathophysiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminFragile X SyndromeFragile X Messenger Ribonucleoprotein 1AnimalsMiceMaleMice, KnockoutMechanistic Target of Rapamycin Complex 1Disease Models, AnimalSignal Transduction

Stichwörter der Autor:innen

Fmr1 KO mouse modelautism spectrum disorderfragile X syndromemTORC1 and ERK signaling pathwaysmetformin

Substanzen

MetforminFragile X Messenger Ribonucleoprotein 1Mechanistic Target of Rapamycin Complex 1Fmr1 protein, mouse

Autor:innen und Institutionen

  • Department of Biochemistry, Goodman Cancer Institute, McGill University, Montreal, QC H3A 1A3, Canada.

ORCID-Profile: Jung-Hyun Choi, Laura Marsal-García, Eve Peraldi, Ilse Gantois, Nahum Sonenberg

Förderung

  • Canadian Government | Canadian Institutes of Health Research (CIHR)
  • National Research Foundation of Korea (NRF)
  • FRAXA Research Foundation (FRF)

Zitieren

APA

Choi, J. H., Marsal-García, L., Peraldi, E., Walters, C., Huang, Z., Gantois, I., & Sonenberg, N. (2024). Early metformin treatment: An effective approach for targeting fragile X syndrome pathophysiology. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2407546121

Vancouver

Choi JH, Marsal-García L, Peraldi E, Walters C, Huang Z, Gantois I, et al. Early metformin treatment: An effective approach for targeting fragile X syndrome pathophysiology. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2407546121

BibTeX
@article{Choi2024,
  author = {Choi, Jung-Hyun and Marsal-García, Laura and Peraldi, Eve and Walters, Caleb and Huang, Ziying and Gantois, Ilse and Sonenberg, Nahum},
  title = {Early metformin treatment: An effective approach for targeting fragile X syndrome pathophysiology},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  doi = {10.1073/pnas.2407546121}
}
Kostenlos starten →